Peptide Stacking: Which Peptides Can Be Combined, Which Conflict, and How to Build a Protocol That Makes Sense

Peptide stacking means running multiple peptides simultaneously to target different physiological goals or to amplify a single goal through complementary mechanisms. The ipamorelin + CJC-1295 combination (a ghrelin mimetic + GHRH analog) is the classic synergistic stack — each peptide activates a different receptor pathway on pituitary somatotroph cells, and together they produce 2-3x the GH release of either alone. That is a rational stack: two different mechanisms targeting the same outcome with multiplicative rather than additive effects. A redundant stack would be ipamorelin + GHRP-6 + hexarelin — three ghrelin mimetics all competing for the same GHS-R1a receptor. You do not get 3x the GH release because the receptor has a saturation point. You get slightly more GH than any one alone (maybe 1.3-1.5x at most) plus the combined side effect profiles of all three (GHRP-6's appetite stimulation, hexarelin's cortisol and prolactin elevation). This is spending more money and tolerating more side effects for marginally more output. A conflicting stack is harder to identify but does exist. Running a GH-releasing peptide alongside somatostatin or a somatostatin analog (octreotide) would directly counteract the GH release — somatostatin inhibits GH secretion. More subtle conflicts involve downstream pathway competition: BPC-157's anti-inflammatory mechanism involves modulating nitric oxide pathways that can theoretically interact with peptides that affect blood pressure or vascular tone, though clinically significant interactions at therapeutic doses are not well-documented. This content is for research and educational purposes only. It does not constitute medical advice. Consult a qualified healthcare provider for all protocol decisions.

The best peptide stacks combine peptides that work through different receptor systems or target different physiological goals. Here are the combinations with the strongest rationale. GH secretagogue stack (ipamorelin + CJC-1295 without DAC): the gold standard. Ipamorelin activates GHS-R1a (ghrelin receptor). CJC-1295 activates the GHRH receptor. Both are on pituitary somatotroph cells. Together, they produce a synergistic GH pulse that exceeds what either produces alone — the GHRH analog primes the somatotroph to be more responsive to the ghrelin mimetic signal. This is one of the best-documented peptide synergies in the literature. Typical combined dose: ipamorelin 200-300 mcg + CJC-1295 (Mod-GRF) 100-200 mcg, injected together subcutaneously 2-3x daily. Healing stack (BPC-157 + TB-500): BPC-157 (Body Protection Compound-157) promotes angiogenesis (new blood vessel formation), nitric oxide signaling, and upregulates growth factor receptors at the injury site. TB-500 (thymosin beta-4 fragment) promotes cell migration, anti-inflammatory signaling, and tissue remodeling. The mechanisms are complementary — BPC-157 brings blood supply to the injury, TB-500 promotes the cellular repair process. Many providers report faster tendon, ligament, and muscle healing with the combination compared to either alone, though formal head-to-head studies in humans are lacking. Typical combined protocol: BPC-157 250-500 mcg + TB-500 750-2000 mcg daily (injected subcutaneously, ideally near the injury site for BPC-157). GH + healing stack (ipamorelin/CJC + BPC-157): GH elevation supports tissue repair through IGF-1-mediated pathways. BPC-157 targets the local injury environment. The combination addresses recovery at both systemic (GH/IGF-1) and local (BPC-157 at the injury site) levels. Athletes recovering from significant injuries (tendon tears, post-surgical) are the primary use case. Metabolic stack (semaglutide + a GH secretagogue): semaglutide reduces appetite and improves insulin sensitivity. GH secretagogues promote lipolysis (fat mobilization) and preserve lean mass during caloric deficit. The combination theoretically supports fat loss through complementary mechanisms — appetite reduction (semaglutide) plus fat mobilization and muscle preservation (GH). The practical concern: monitoring insulin sensitivity carefully, because GH can antagonize insulin signaling while semaglutide improves it. The net effect on glucose homeostasis needs to be tracked through fasting glucose and HbA1c. Dosed logs all peptides on a single timeline with per-injection dosing, making it easy to track multi-peptide protocols and correlate timing with subjective responses.

How and when you administer peptides affects their efficacy — sometimes dramatically. Getting the logistics right is the difference between an optimized stack and an expensive waste. Fasting matters for GH secretagogues. Insulin and carbohydrate intake blunt GH release by stimulating somatostatin (the GH-suppressing hormone). A 2003 study in Growth Hormone & IGF Research showed that GH response to ghrelin mimetics was reduced by approximately 40% when administered after a carbohydrate-containing meal compared to fasting. The practical rule: inject GH secretagogues on an empty stomach — at least 30 minutes before eating or 2+ hours after eating. The best timing windows: upon waking (fasted), mid-afternoon (if fasted from lunch for 2+ hours), and before bed (at least 2 hours after dinner). The pre-bed injection is particularly effective because it coincides with the natural nocturnal GH surge during deep sleep. Fasting does NOT matter for BPC-157, TB-500, or semaglutide. These peptides work through mechanisms that are not affected by insulin or carbohydrate status. Inject them whenever is convenient for your schedule. Mixing in the same syringe: ipamorelin and CJC-1295 (Mod-GRF) can be mixed in the same syringe and injected together — they are compatible peptides that are commonly reconstituted together. BPC-157 and TB-500 can also be mixed if injected subcutaneously. Do NOT mix peptides you are not certain are compatible — some peptides have different pH requirements or buffer compositions that can cause degradation when combined in the same vial. Injection site: subcutaneous injection in the abdominal fat is the standard for most peptides. For BPC-157 specifically, subcutaneous injection near the injury site may produce better local results — the peptide achieves higher local concentrations at the injury compared to a distant injection site. The evidence for this is mostly clinical observation and animal data rather than controlled human studies, but the rationale is pharmacokinetically sound. Rotate injection sites to prevent lipodystrophy (tissue changes from repeated injections in the same spot). Alternate between left and right sides of the abdomen, and move the exact location by 1-2 inches each time.

Multiple ghrelin mimetics (e.g., ipamorelin + GHRP-6 + hexarelin): all three compete for GHS-R1a. You get diminishing returns on GH release with each additional ghrelin mimetic, but you accumulate the side effects of all three. GHRP-6 increases appetite significantly (via peripheral ghrelin receptors in the stomach). Hexarelin raises cortisol and prolactin more than ipamorelin. Running all three gives you the appetite increase, the cortisol/prolactin elevation, and marginally more GH than ipamorelin alone. Not worth it. Pick one ghrelin mimetic — ipamorelin for most people — and pair it with a GHRH analog instead. Multiple GHRH analogs (e.g., CJC-1295 with DAC + sermorelin): same issue. Both activate the GHRH receptor. CJC-1295 with DAC has a half-life of 6-8 days, so adding sermorelin (half-life ~12 minutes) on top provides no additional benefit — the receptor is already occupied by CJC-1295. Choose one GHRH analog based on your preferred dosing schedule: CJC-1295 with DAC for weekly dosing convenience, CJC-1295 without DAC (Mod-GRF) or sermorelin for daily pulsatile dosing. GH secretagogues + exogenous GH simultaneously at full doses: exogenous GH suppresses pituitary GH production through negative feedback. If you are injecting 2-4 IU of exogenous GH, your pituitary is already suppressed — adding a secretagogue to stimulate a suppressed pituitary is like pressing the gas pedal with the parking brake on. The exception: alternating days (exogenous GH on workout days, secretagogues on rest days) can maintain pituitary responsiveness while still providing reliable GH elevation. See our GH vs secretagogues article for details. Stacking more than 3-4 peptides simultaneously: beyond practical considerations (cost, injection frequency, storage), running too many variables simultaneously makes it impossible to determine what is working and what is not. If you start ipamorelin + CJC-1295 + BPC-157 + TB-500 + semaglutide on the same day and your sleep improves, your knee pain decreases, and your appetite drops — which peptide did what? You cannot tell. Start with one stack (GH or healing), run it for 4-6 weeks, establish a baseline response, then add the next peptide. This sequential introduction lets you attribute effects to specific compounds. Dosed is specifically designed for this — tracking each peptide with its own dosing log alongside subjective markers lets you see exactly when changes occurred relative to what you started or adjusted.